Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Ronald Silver Sells 12,048 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 12,048 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $21,204.48. Following the sale, the insider now owns 279,655 shares in the company, valued at approximately $492,192.80. This trade represents a 4.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $1.92 on Friday. The firm’s fifty day moving average price is $3.57 and its 200 day moving average price is $4.15. The company has a market capitalization of $307.25 million, a price-to-earnings ratio of -64.00 and a beta of 0.29. Ironwood Pharmaceuticals, Inc. has a 12 month low of $1.59 and a 12 month high of $15.65.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. KBC Group NV grew its position in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,198 shares during the last quarter. Journey Strategic Wealth LLC purchased a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $45,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $47,000. Envestnet Asset Management Inc. purchased a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $50,000. Finally, Xponance Inc. purchased a new position in Ironwood Pharmaceuticals during the 4th quarter worth $50,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, JMP Securities reduced their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $10.67.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.